Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

Annual Review of Immunology

Volumn 19, Issue , 2001, Pages 225-252

  Salomon, B ^a   Bluestone, J A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B7; CD28; T cell costimulation; Tolerance

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL MIGRATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELL DIFFERENTIATION; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MACROMOLECULAR SUBSTANCES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; SELF TOLERANCE; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; TRANSPLANTATION IMMUNOLOGY;

EID: 0035059417     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.19.1.225     Document Type: Review

References (163)

1. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo
2. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation
3. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T cell clones
4. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells
5. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule
6. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig
7. Immunosuppressive effects of human CTLA4-Ig in a non-human primate model of allogeneic pancreatic islet transplantation
8. Transplantation tolerance induced by CTLA4-Ig
9. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
10. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
11. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody
12. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade
13. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease
14. The role of costimulation in autoimmune demyelination
15. The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system
16. The role of T cell costimulatory activation pathways in transplant rejection
17. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response
18. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation
19. Distinct roles for LFA-1 and CD28 during activation of naive T cells: Adhesion versus costimulation
20. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Thl cytokine production
21. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response
22. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: Effector function is linked to proliferative capacity
23. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway
24. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28
25. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells
26. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL
27. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4
28. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo
29. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival
30. The roles of CD28 and CD40 ligand in T cell activation and tolerance
31. T cell activation determined by T cell receptor number and tunable thresholds
32. T lymphocyte costimulation mediated by reorganization of membrane microdomains
33. A receptor/cytoskeletal movement triggered by costimulation during T cell activation
34. Absence of B7-dependent responses in CD28-deficient mice
35. Duration of TCR stimulation determines costimulatory requirement of T cells
36. High concentrations of antigenic ligand activate and do not tolerize naive CD4 T cells in the absence of CD28/B7 costimulation
37. CD28 costimulation is crucial for the development of spontaneous autoimmune encephalomyelitis
38. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells
39. + T cells
40. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells
41. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation
42. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells
43. Induction of autoimmunity in the absence of CD28 costimulation
44. CD28-deficient mice are highly resistant to collagen-induced arthritis
45. B7.2 has opposing roles during the activation versus effector stages of experimental autoimmune thyroiditis
46. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis
47. Genetic and molecular aspects of demyelination
48. Immunopathogenesis of multiple sclerosis
49. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation
50. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
51. A critical role for BT/CD28 costimulation in experimental autoimmune encephalomyelitis: A comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade
52. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice
53. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein
54. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE
55. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis
56. Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis
57. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system
58. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis
59. CTLA-4-Fc treatment of ongoing EAE improves recovery but has no effect upon relapse rate. Implications for the mechanisms involved in disease perpetuation
60. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis
61. Spreading oft cell autoimmunity to cryptic determinants of an autoantigen
62. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis
63. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment
64. + T cells in the pathogenesis of organ-specific autoimmune diseases
65. + T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway
66. CD28 costimulation promotes the production of Th2 cytokines
67. LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production
68. CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen
69. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat
70. Cytokines that regulate autoimmune responses
71. CD28/B7 regulation of Thl and Th2 subsets in the development of autoimmune diabetes
72. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism
73. Treatment of murine lupus with CTLA4Ig
74. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule
75. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation
76. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways
77. Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation
78. + T cells
79. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis
80. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis
81. Experimental autoimmune meningitis: A novel neurological disease in CD28-deficient mice
82. Regulatory T cells: Key controllers of immunologic self-tolerance
83. + immunoregulatory T cells that control autoimmune diabetes
84. T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes
85. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen
86. Coexpression of B7-1 and viral ("self") transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes
87. Molecular basis of T cell inactivation by CTLA-4
88. Regulation of surface and intracellular expression of CTLA4 on mouse T cells
89. CTLA-4 ligation blocks CD28-dependent T cell activation
90. CTLA-4 can function as a negative regulator of T cell activation
91. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
92. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
93. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
94. + T cells
95. Cutting edge: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous
96. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
97. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70
98. The emerging role of CTLA-4 as an immune attenuator
99. Structural analysis of CTLA-4 function in vivo
100. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152)
101. + regulatory cells that control intestinal inflammation
102. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
103. + T cells
104. CTLA-4 regulates tolerance induction and T cell differentiation in vivo
105. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses
106. The role of CTLA-4 in regulating Th2 differentiation
107. Stimulation of transforming growth factor-beta 1 transcription by cyclosporine
108. CTLA-4: A negative regulator of autoimmune disease
109. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis
110. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis
111. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis
112. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes
113. Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population
114. Genetic and physical mapping of a type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-CTLA4-D2S105 on chromosome 2q33
115. The CTLA-4 gene is expressed in placental fibroblasts
116. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases
117. Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease
118. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
119. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies
120. CD28/B7 system of T cell costimulation
121. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells
122. The complexities of T cell co-stimulation: CD28 and beyond
123. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2
124. Pancreatic expression of B7 co-stimulatory molecules in the nonobese diabetic mouse
125. Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjogren's syndrome (SS) through up-regulated Th2 response
126. Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Fas lpr mice
127. Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis
128. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions
129. Costimulatory molecules B7-1 and B7-2 on CSF cells in multiple sclerosis and optic neuritis
130. + B cells in active multiple sclerosis and reversal by interferon beta-1b therapy
131. B7-1 (CD80), B7-2 (CD86), interleukin-12 and transforming growth factor- beta mRNA expression in CSF and peripheral blood mononuclear cells from multiple sclerosis patients
132. New perspectives of CD28-B7-mediated T cell costimulation
133. Structure and dimerization of a soluble form of B7-1
134. T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo
135. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis
136. Blockade of T cell costimulation prevents development of experimental chronic renal allograft rejection
137. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2
138. Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts
139. Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival
140. Costimulatory blockade by the induction of an endogenous xenospecific antibody response
141. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway
142. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway
143. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
144. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154
145. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154
146. + T cell apoptosis but not immune deviation
147. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
148. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients
149. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism
150. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo
151. + T cells and prolonged graft survival in a CTLA4-dependent manner
152. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection
153. Induction of islet transplantation tolerance using donor specific transfusion and anti-CD154 monoclonal antibody
154. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand
155. + T cells, interferon-gamma, and CTLA4
156. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand
157. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients
158. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice
159. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
160. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways
161. The in vivo mechanism of action of CTLA4Ig
162. Transplantation of anergic histoincompatible bone marrow allografts
163. CTLA4Ig-mediated blockade of T cell costimulation in patients with psoriasis vulgaris